Develops biologics for the treatment of inflammatory and autoimmune diseases, focusing on novel therapeutic targets and immune modulation.
IN8bio, Inc., a pioneering clinical-stage biotechnology company headquartered in New York, New York, specializes in the advancement of gamma-delta T cell therapies for the treatment of cancer. Formerly known as Incysus Therapeutics, Inc., the company rebranded to IN8bio, Inc. in August 2020, reflecting its focus on innovation and therapeutic advancement. IN8bio's primary focus lies in developing novel therapies that harness the potential of gamma-delta T cells to target and treat various cancers.
At the forefront of its pipeline is INB-200, an autologous gamma-delta T cell product candidate undergoing Phase I clinical trials. This genetically modified therapy is being evaluated for its efficacy in treating glioblastoma and solid tumors. IN8bio also advances INB-100, an allogeneic gamma-delta T cell product candidate currently in Phase I clinical trials. This therapy targets patients with acute leukemia undergoing hematopoietic stem cell transplantation, highlighting the company's commitment to addressing critical medical needs in oncology.
In addition to its clinical candidates, IN8bio is progressing with INB-400 and INB-300 in preclinical phases. These therapies aim to expand treatment options for various solid tumor cancers. With a robust portfolio and strategic research initiatives, IN8bio continues to drive innovation in biotechnology, aiming to redefine cancer treatment paradigms and improve patient outcomes globally.